I'm LongbridgeAI, I can summarize articles.Needham analyst Joseph Stringer maintained a Buy rating on Annexon Biosciences with an unchanged $25 price target. The decision is driven by strategic flexibility in the Phase 3 ARCHER II trial for geographic atrophy, specifically a new Month 24 dual primary endpoint that adds upside potential without compromising the robust Month 15 analysis. Stringer notes manageable timing and costs, reinforcing confidence in the company's clinical execution and long-term value.
Needham analyst Joseph Stringer maintained a Buy rating on Annexon Biosciences today and set a price target of $25.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Joseph Stringer has given his Buy rating due to a combination of factors, notably the added strategic flexibility in Annexon’s Phase 3 ARCHER II trial in geographic atrophy. The introduction of a separate Month 24 dual primary endpoint builds in additional upside potential, as the extended visual acuity data could materially strengthen the overall efficacy profile if results are favorable.
At the same time, the trial’s design remains robust, with the Month 15 primary analysis still well powered and overseen by an independent data monitoring committee, limiting incremental risk from the protocol change. Stringer also highlights that the timing and cost of these adjustments are manageable, supporting his unchanged $25 price target and reinforcing confidence in Annexon’s long-term value proposition and clinical execution.
According to TipRanks, Stringer is a 5-star analyst with an average return of 25.1% and a 48.78% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Phathom Pharmaceuticals, and Annexon Biosciences.
In another report released on August 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.